Total Payments
$37,071
2024 Payments
$24.26
Companies
7
Transactions
39
Medicare Patients
706
Medicare Billing
$70,698
Payment Breakdown by Category
Consulting$19,520 (52.7%)
Other$12,625 (34.1%)
Travel$4,416 (11.9%)
Food & Beverage$510.39 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $19,520 | 10 | 52.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,625 | 2 | 34.1% |
| Travel and Lodging | $4,416 | 13 | 11.9% |
| Food and Beverage | $510.39 | 14 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $24,847 | 28 | $0 (2019) |
| Roche Diagnostics Corporation | $2,900 | 1 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $2,660 | 4 | $0 (2017) |
| Roche Molecular Systems, Inc. | $2,000 | 1 | $0 (2017) |
| GlaxoSmithKline, LLC. | $1,950 | 1 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,400 | 1 | $0 (2020) |
| Gilead Sciences, Inc. | $1,314 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24.26 | 1 | Gilead Sciences, Inc. ($24.26) |
| 2022 | $1,950 | 1 | GlaxoSmithKline, LLC. ($1,950) |
| 2021 | $1,260 | 1 | Gilead Sciences, Inc. ($1,260) |
| 2020 | $4,300 | 2 | Roche Diagnostics Corporation ($2,900) |
| 2019 | $12,693 | 10 | Merck Sharp & Dohme Corporation ($12,693) |
| 2017 | $16,844 | 24 | Merck Sharp & Dohme Corporation ($12,154) |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.26 | General |
| 04/12/2022 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 06/29/2021 | Gilead Sciences, Inc. | Veklury (Drug) | Consulting Fee | Cash or cash equivalent | $1,260.00 | General |
| Category: COVID-19 | ||||||
| 12/08/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 07/16/2020 | Roche Diagnostics Corporation | MD Cobas Instruments and Reagents (Device) | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| Category: Molecular Diagnostics | ||||||
| 12/11/2019 | Merck Sharp & Dohme Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,625.00 | General |
| 12/11/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/28/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $41.91 | General |
| 11/28/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $23.19 | General |
| 11/27/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $24.15 | General |
| 11/26/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $20.00 | General |
| 11/25/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $1,041.95 | General |
| 11/25/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $645.99 | General |
| 11/25/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $90.66 | General |
| 11/25/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $30.18 | General |
| 12/15/2017 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $4,675.00 | General |
| 12/15/2017 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 12/09/2017 | Merck Sharp & Dohme Corporation | ZOLINZA (Drug), CANCIDAS, NOXAFIL | Travel and Lodging | In-kind items and services | $403.00 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2017 | Merck Sharp & Dohme Corporation | ZOLINZA (Drug), CANCIDAS, NOXAFIL | Travel and Lodging | In-kind items and services | $403.00 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2017 | Merck Sharp & Dohme Corporation | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $47.26 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/08/2017 | Merck Sharp & Dohme Corporation | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $35.11 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/08/2017 | Merck Sharp & Dohme Corporation | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $33.76 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/07/2017 | Merck Sharp & Dohme Corporation | PREVYMIS (Drug) | Travel and Lodging | In-kind items and services | $414.52 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/07/2017 | Merck Sharp & Dohme Corporation | PREVYMIS (Drug) | Travel and Lodging | In-kind items and services | $179.18 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/07/2017 | Merck Sharp & Dohme Corporation | PREVYMIS (Drug) | Travel and Lodging | In-kind items and services | $130.46 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 158 | 205 | $75,329 | $17,493 |
| 2022 | 7 | 183 | 229 | $77,090 | $17,943 |
| 2021 | 7 | 200 | 255 | $33,070 | $18,979 |
| 2020 | 5 | 165 | 215 | $25,763 | $16,282 |
Total Patients
706
Total Services
904
Medicare Billing
$70,698
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 59 | 95 | $34,806 | $8,356 | 24.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 38 | 38 | $21,330 | $3,742 | 17.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 13 | $5,785 | $1,845 | 31.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 29 | $7,853 | $1,785 | 22.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 13 | 13 | $3,770 | $1,318 | 35.0% |
| 99451 | Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | Facility | 2023 | 14 | 17 | $1,785 | $447.68 | 25.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 53 | 89 | $31,867 | $6,936 | 21.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 32 | 32 | $9,280 | $3,098 | 33.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 14 | $6,230 | $2,013 | 32.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 28 | 35 | $9,422 | $1,912 | 20.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 17 | 17 | $9,571 | $1,723 | 18.0% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 22 | 22 | $8,620 | $1,694 | 19.7% |
| 99451 | Telephone or internet assessment with written report by consulting physician, 5 minutes or more | Facility | 2022 | 17 | 20 | $2,100 | $568.06 | 27.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 55 | 57 | $7,826 | $5,007 | 64.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 34 | 56 | $8,871 | $4,371 | 49.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 35 | 55 | $5,376 | $2,920 | 54.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 14 | 14 | $2,512 | $2,040 | 81.2% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 25 | 25 | $3,955 | $1,960 | 49.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 18 | 18 | $2,774 | $1,924 | 69.4% |
| 99451 | Telephone or internet assessment and management service provided by consultative physician with written report, 5 minutes or more of medical consultative discussion and review | Facility | 2021 | 19 | 30 | $1,756 | $756.72 | 43.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 30 | 55 | $6,193 | $4,495 | 72.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 49 | 51 | $5,865 | $4,231 | 72.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 44 | 66 | $6,880 | $3,655 | 53.1% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 27 | 28 | $4,367 | $2,265 | 51.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 15 | 15 | $2,458 | $1,636 | 66.6% |
About Dr. Raymund Razonable, M.D
Dr. Raymund Razonable, M.D is a Infectious Disease healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750351805.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raymund Razonable, M.D has received a total of $37,071 in payments from pharmaceutical and medical device companies, with $24.26 received in 2024. These payments were reported across 39 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($19,520).
As a Medicare-enrolled provider, Razonable has provided services to 706 Medicare beneficiaries, totaling 904 services with total Medicare billing of $70,698. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease
- Location Rochester, MN
- Active Since 01/23/2006
- Last Updated 08/19/2020
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1750351805
Products in Payments
- MD Cobas Instruments and Reagents (Device) $2,900
- CFZ533 (Biological) $2,660
- MOLECULAR DIAGNOSTICS RESEARCH & DEVELOPMENT (Device) $2,000
- Veklury (Drug) $1,260
- PREVYMIS (Drug) $931.07
- ZOLINZA (Drug) $806.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Rochester
Robin Patel, M.d, M.D
Infectious Disease — Payments: $270,548
Infectious Disease $270,548
Ann Falsey, Md, MD
Infectious Disease — Payments: $191,692
Infectious Disease $191,692
Edward Walsh, Md, MD
Infectious Disease — Payments: $131,419
Infectious Disease $131,419
Emil Lesho, D.o, D.O
Infectious Disease — Payments: $65,937
Infectious Disease $65,937
Zelalem Temesgen, M.d, M.D
Infectious Disease — Payments: $56,223
Infectious Disease $56,223
Dr. Angela Branche, Md, MD
Infectious Disease — Payments: $50,957
Infectious Disease $50,957